Repurposed Drugs in Gastric Cancer

Authors:
Open Access
Publisher website
Google Scholar
Abstract
Gastric cancer (GC) is one of the major causes of death worldwide, ranking as the fifth most incident cancer in 2020 and the fourth leading cause of cancer mortality. The majority of GC patients are in an advanced stage at the time of diagnosis, presenting a poor prognosis and outcome. Current GC treatment approaches involve endoscopic detection, gastrectomy and chemotherapy or chemoradiotherapy in an adjuvant or neoadjuvant setting. Drug development approaches demand extreme effort to identify molecular mechanisms of action of new drug candidates. Drug repurposing is based on the research of new therapeutic indications of drugs approved for other pathologies. In this review, we explore GC and the different drugs repurposed for this disease.
Funding Information
  • FEDER—Fundo Europeu de Desenvolvimento Regional funds (IF/00092/2014/CP1255/CT0004)
  • Portuguese funds (IF/00092/2014/CP1255/CT0004)

This publication has 331 references indexed in Scilit: